We have applied our expertise in multivalency to discover product candidates and lead compounds in a number of therapeutic areas.
We believe that our lead product candidates have demonstrated in relevant preclinical models, potential advantages such as substantial increases in potency, duration of action and/or selectivity relative to existing medicines or potential medicines in late-stage clinical studies.
The table below summarizes the status of our most advanced product candidates for internal development or co-development. The table also includes the status of respiratory programs in which we have an economic interest that are being developed and commercialized by GSK pursuant to agreements with Theravance, Inc., now known as Innoviva, Inc.
Infectious Disease
Collaborators: Multiple (ex-U.S.)¹
Phase 1
Phase 2
Phase 3
Filed
Approved
Cefilavancin (TD-1792): Gram+ MRSA
Collaborators: R-Pharm (ex-U.S.)
Phase 1
Phase 2
Phase 3
Respiratory
Revefenacin (TD-4208): COPD
Collaborators: Mylan
Phase 1
Phase 2
Phase 3
Filed
Gastrointestinal
Velusetrag: Gastroparesis
Collaborators: Alfa Wassermann (ex-U.S.)
Phase 1
Phase 2
TD-8954: ICU IV Prokinetic
Collaborators: Takeda
Phase 1
Phase 2
TD-1473: Ulcerative Colitis, Crohn’s Disease
Collaborators: Janssen Biotech
Phase 1
Cardiovascular
TD-9855: nOH
Phase 1
Phase 2
TD-0714, TD-1439: Heart Failure, Chronic Kidney Disease
Phase 1
Economic Interests
Trelegy Ellipta (FF/UMEC/VI): COPD
Collaborators: GSK & Innoviva, Inc.²
Phase 1
Phase 2
Phase 3
Filed
Approved
Trelegy Ellipta (FF/UMEC/VI): Asthma
Collaborators: GSK & Innoviva, Inc.²
Phase 1
Phase 2
Phase 3
MABA, MABA/ICS (batefenterol, batefenterol/FF): COPD
Collaborators: GSK & Innoviva, Inc.²
Phase 1
Phase 2
Notes:
¹ Concurrent bacteremia data added to U.S. label for approved indications (cSSSI & HABP/VABP)
² We hold economic interest in future payments that may be made by GlaxoSmithKline plc (GSK) relating to certain programs, including “Closed Triple” (FF/UMEC/VI) (Fluticasone Furoate/Umeclidinium/Vilanterol), MABA/FF (batefenterol/FF), MABA monotherapy and other future products that may be combined with VI or MABA (batenfenterol)
Key:
- CNS: Central Nervous System
- COPD: Chronic Obstructive Pulmonary Disease
- cSSSI: Complicated Skin and Skin Structure Infections
- FF: Fluticasone Furoate
- GI: Gastrointestinal
- HABP/VABP: Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
- HCV: Hepatitis C Virus
- ICS: Inhaled Corticosteriod
- MABA: Bifunctional Muscarinic Antagonist-Beta2 Agonist
- MRSA: Methicillin-Resistant Staphylococcus Aureus
- nOH: Neurogenic Orthostatic Hypotension
- OIC: Opioid-Induced Constipation
- UMEC: Umeclidinium
- VI: Vilanterol
In the table above:
- Status indicates the most advanced stage of clinical development that has been completed or is in process.
- Phase 1 indicates initial clinical safety testing in healthy volunteers, or studies directed toward understanding the mechanisms of action of the drug.
- Phase 2 indicates further clinical safety testing and preliminary efficacy testing in a limited patient population.
- Phase 3 indicates evaluation of clinical efficacy and safety within an expanded patient population.
- Filed indicates that a marketing application has been submitted to a regulatory authority.
